Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
TSHA
#1816
Taysha Gene Therapies, Inc. Common Stock
4.5
3
+0.44%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+0.44%
Monatliche Änderung
-4.43%
6 month change
+51.51%
Jahresänderung
+177.91%
Vorheriger Schlusskurs
4.5
1
Open
4.5
3
Bid
Ask
Low
4.5
3
High
4.5
3
Volumen
115
Märkte
Aktien
Gesundheitswesen
TSHA
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
37.76 M
38.47 M
63.47 M
187.02 M
205 M
—
Valuation ratios
Enterprise value
750.94 M
299.12 M
51.76 M
175.86 M
215.62 M
1.31 B
Price to earnings ratio
—
—
-0.58
-1.78
-4.81
-25.6
Price to sales ratio
—
—
38.68
12.85
51.93
318.86
Price to cash flow ratio
—
—
1.09
2.72
5.33
28.41
Price to book ratio
—
—
101.89
2.65
6.05
10.2
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.23
0.82
1.31
0.65
0.56
0.46
Return on equity %
0.24
1.83
174.94
1.49
1.25
0.91
Return on invested capital %
5 101.07
2 243.62
845.6
456.59
882.31
1 286.18
Gross margin %
—
100
100
100
100
—
Operating margin %
—
-15.75 K
6 497.88
468.83
1 097.55
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
—
-15.87 K
6 640.56
722.06
1 071.62
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
36.17
3.08
1.54
4.08
5.42
33.72
Inventory turnover
—
—
—
—
—
—
Asset turnover
—
-0
0.01
0.1
0.05
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
—
0.17
0.3
0.23
0.27
0.86
Long term debt to total equity ratio
—
0.39
40.01
0.54
0.61
1.78
Per share metrics
Operating cash flow per share
—
—
2.01
0.63
0.32
0.29
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
—
—
2
1.24
0.56
2.88
Net current asset value per share
—
—
2.19
1.29
0.57
2.93
Tangible book value per share
—
—
0.02
0.65
0.29
1.94
Working capital per share
—
—
0.77
0.97
0.46
2.57
Book value per share
—
—
0.02
0.65
0.29
1.94
Nachrichten
Taysha Gene Therapies: F&E-Leiter verkauft Aktien im Wert von 942.000 US-Dollar
Neurogene: Stifel bekräftigt "Buy"-Rating und verweist auf solide Sicherheitsmarge
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Rett-Syndrom: Taysha behandelt ersten Patienten in zulassungsrelevanter Gentherapie-Studie
Taysha doses first patient in pivotal Rett syndrome gene therapy trial
Autolus Therapeutics: Needham hebt Kursziel an – Aktie legt deutlich zu
Taysha Gene Therapies: Aktie erreicht 52-Wochen-Hoch bei 5,98 US-Dollar
Taysha Gene Therapies stock hits 52-week high at $5.98
Biotech-Aktien: Jefferies nennt seine 6 Top-Picks für 2026/n
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026
Taysha Gene Therapies: Citizens bekräftigt "Market Outperform"-Rating
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock